Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.64
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 12, 23 | EF Hutton | maintain | Buy | Buy |
| Mar 9, 23 | EF Hutton | maintain | Buy | Buy |
| Dec 29, 22 | EF Hutton | maintain | Buy | Buy |
| Aug 25, 22 | EF Hutton | maintain | Buy | Buy |
| Apr 7, 22 | EF Hutton | maintain | Buy | Buy |
| Jan 13, 20 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 13, 20 | H.C. Wainwright | maintain |
Daily · Wilder smoothing
| Buy |
| Buy |
| Feb 20, 13 | Taglich Brothers | maintain | Speculative Buy | Buy |
| Feb 13, 13 | Chardan Capital | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.79 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 9.27 | Oscillator | Buy |
| Williams %R (14) | -89.47 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.04 (Hist -0.06) | Oscillator | Strong Sell |
| Average Directional Index (14) | 28.14 (+DI 24.9 / -DI 21.8) | Trend | Strong Buy |
| EMA 20 | 1.77 | MA | Strong Sell |
| SMA 20 | 1.90 | MA | Strong Sell |
| EMA 50 | 1.72 | MA | Strong Sell |
| SMA 50 | 1.70 | MA | Strong Sell |
| SMA 200 | 2.61 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Talor Eyal | officer: Chief Scientific Officer | A-Award | 1,165 @ $2.06 | $2.40K |
| Sep 30, 26 | Prichep Patricia B | officer: Chief Financial Officer | A-Award | 2,082 @ $2.06 | $4.29K |
| Sep 30, 26 | Kersten Geert R | director, officer: Chief Executive Officer | A-Award | 2,621 @ $2.06 | $5.40K |
| Aug 25, 26 | Kersten Geert R | director, officer: Chief Executive Officer | P-Purchase | 100,000 @ $1.38 | $138.0K |
| Aug 14, 26 | Watson Robert Eugene | director | A-Award | 110,000 @ $1.49 | $163.9K |
| Aug 14, 26 | Baillavoine Bruno Jean-Marie | director | A-Award | 110,000 @ $1.49 | $163.9K |
| Aug 14, 26 | Cipriano John | officer: Senior Vice President | A-Award | 80,000 @ $1.49 | $119.2K |
| Aug 14, 26 | Talor Eyal | officer: Chief Scientific Officer | A-Award | 250,000 @ $1.49 | $372.5K |
| 4 | Aug 26, 2026 | 2026-08-26 08:32:37 | View |
| 4 | Aug 17, 2026 | 2026-08-17 09:43:35 | View |
| 4 | Aug 17, 2026 | 2026-08-17 09:37:09 | View |
| 4 | Aug 17, 2026 | 2026-08-17 09:33:22 | View |
| 4 | Aug 17, 2026 | 2026-08-17 09:27:11 | View |
| 4 | Aug 17, 2026 | 2026-08-17 09:23:08 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | CVM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.6x | -5.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.5x | EPS est. -3.07 | Discount |
| Price / Book | 1.8x | 5.5x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -1.6x | -5.7x | Discount |
| Return on equity | -202.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.72 | 0.66 | Moderate |
| Piotroski / Altman Z | 2/9 | Z -38.12 | Distress |
Discounted cash flow model
Stock news · updated daily
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | — | -0.47 | — | — |
| May 18, 2026 | — | -0.67 | — | — |
| Feb 17, 2026 | — | -0.68 | — | — |
| Dec 29, 2025 | — | -0.76 | — | — |
| Aug 14, 2025 | — | -1.36 | — | — |
| May 14, 2025 | — | -2.40 | — | — |